. Success during in-vitro maturation (IVM) of oocyte treatment is dependent on the numbers of oocytes retrieved which are predicted by early follicular phase transvaginal ultrasound measurement of the antral follicle count and peak ovarian stromal blood flow velocity Child T.J., Gulekli B. and Tan S.L.
Introduction: Human germinal vesicle stage oocytes can be aspirated by the ultrasound guided transvaginal approach from proliferating antral follicular stages (4-12 mm diameter) even when no human chorionic gonadotrophin (HCG) has been administered. Oocyte retrieval of immature oocytes is similar to that of mature oocytes, although a more rigid, double lumen needle with a reduced length and short bevel using low suction pressure have been suggested.
Materials and methods:
Patients Ͻ35 years of age, with regular menstrual cycles and a body mass index of ഛ30 kg/m 2 , undergoing a laparoscopy and dye or laparoscopic sterilization were recruited for the study. Volunteers received a truncated course of rFSH: 300, 150 and 150 IU on days 2, 4 and 6 of the menstrual cycle. Transvaginal oocyte recovery was performed on days 7 and 9 of the cycle prior to the laparoscopic procedure under general anaesthesia using a specially adapted 16-gauge double lumen needle with a short bevel. The diameter of each follicle was measured in two planes before being punctured and aspirated. Oocytes were matured in serum-free media for 48 h according to previously described methodology. Cumulus coverage and expansion were correlated with oocyte maturation potential.
Results: A total of 28 patients (mean age 29 Ϯ 1.4 years) were recruited into the study. After gonadotrophin priming, 255 follicles were aspirated yielding 146 oocytes (a recovery rate of 57.2%). The mean number of follicles aspirated per patient was 8.9 Ϯ 0.9 (range 2-20) while the mean number of oocytes obtained per patient was 4.7 Ϯ 0.8 (range 0-17). In five patients, a total of 16 oocytes were recovered from 46 follicles using a high aspiration pressure of 120 mmHg (recovery rate of 37.2%). In the remaining 23 patients, a lower aspiration pressure of 80 mmHg was employed, resulting in a significantly improved recovery rate of 61.3% (130 oocytes obtained from 212 follicles). The mean number of oocytes recovered using the high aspiration pressure was 3.1 Ϯ 0.6 compared with 7.9 Ϯ 0.5 when the lower pressure was employed. Furthermore, using the high aspiration pressure, the oocyte recovery rate from small (ഛ 6 mm) and medium sized follicles (6.1-10 mm) (14.2 and 26.1% respectively) was significantly lower than that when the low pressure was used (69.4 and 68% respectively). In contrast, the oocyte recovery rate from follicles Ͼ10 mm was significantly better using the conventional 120 mmHg aspiration pressure compared with 80 mmHg (69.2 versus 40.7%, P Ͻ 0.01). Irrespective of the aspiration pressure, oocyte maturation was positively correlated with follicle size. Oocytes from follicles Ͼ6 mm in diameter were more likely to reach metaphase II after 48 h in culture than those aspirated from follicles ഛ6 mm (55.6 versus 37.5%). The meiotic potential of oocytes with little or no cumulus coverage at the start of culture was impaired compared to those with more than three layers of cumulus (32.1 versus 67.8%).
Conclusions:
The significant improvement in the oocyte recovery rate when the suction pressure was reduced is a testament to the obligatory need of adapting such a pressure, together with a modified needle, for the effective recovery of non-luteinized immature human oocytes. The fact that significantly more oocytes with expanded cumulus mass reached metaphase II reinforces the vital role played by the cumulus cells during the resumption of meiosis. This study also demonstrates a clear relationship between follicular diameter and human oocyte developmental potential in a serum-free medium, with oocytes originating from follicles Ͼ6 mm in diameter being more capable of reaching maturity in vitro. Introduction: Developmental competence of embryos generated from invitro matured (IVM) immature oocytes is invariably low when compared to in-vivo matured oocytes. The maturation of oocytes to the metaphase II stage of meiosis occurs much faster when cultured in-vitro than after invivo superovulation in control animals. Mechanisms within the ovary are likely, therefore, to inhibit the final maturation of the oocyte prior to ovulation. The aims of this study were twofold: (i) to examine the maturation of immature oocytes after being exposed to hypoxanthine (HPX), a known meiosis inhibitor and (ii) to observe their subsequent fertilization and blastocyst development.
Materials and methods:
Three week old female (C57ϫCBA) mice were divided into 4 groups: (i) In-vivo controls; mature (metaphase II, MII) oocytes were collected from superovulated mice. (ii) IVM controls; MII oocytes were collected after 24 h culture in MEM-a medium ϩ 10% fetal calf serum (FCS) ϩ 0.1 IU/ml follicle stimulating hormone (FSH; Gonal F; Serono) ϩ 0.5 IU/ml human chorionic gonadotrophin (HCG; Pregnyl; Organon) ϩ 0.05 mg/ml penicillin. (iii) Pre-HPX culture; Preantral follicles were cultured for 48 h in MEM-a ϩ 10% FCS ϩ 0.041 mg/ml HPX ϩ 0.1 IU/ml FSH ϩ 0.05 mg/ml penicillin. Oocytes were then aspirated from the follicles, washed twice, and IVM performed, as above. (iv) Pre-culture -no supplements; Preantral follicles were cultured for 48 h in MEM-a ϩ 10% FCS ϩ 0.05 mg/ml penicillin only. Oocytes were then aspirated from the follicles, washed twice and IVM performed, as above. IVF was performed on all MII oocytes and the number of 2-cell and blastocyst stage embryos was noted after 24 h and 5 days, respectively.
Results:
It was possible to successfully aspirate oocytes from 85 of the follicles pre-cultured with HPX and 72 pre-cultured with no supplementation. All pre-cultured oocytes were at the GV stage pre-IVM. There were no significant differences in fertilization rates between groups (i), (ii) and (iii).
Conclusions:
The ability of the immature oocyte to mature to the MII stage in-vitro at an accelerated rate compared to in-vivo has been suggested as a likely factor in the reduced embryonic competence observed in oocytes post-IVM. Meiotic inhibitors, such as HPX, may be considered as potentially useful by arresting the meiotic development during oocyte and follicular maturation. This study has shown that HPX is indeed highly effective in arresting meiosis at the GV stage during invitro culture and that this effect can be reversed after the HPX has been removed. However, this was not able to afford the oocyte an improved developmental competence to the blastocyst stage.
10.45-11.00 O-104. Nitric oxide synthase is the initial factor of mammalian oocyte activation
Montag M., Heyers S. and van der Ven H.
Department of Gynaecological Endocrinology and Reproductive
Medicine, University of Bonn, 53105 Bonn, Germany Introduction: A key element of oocyte activation is a rise in intracellular calcium. This has been documented for many species and at least for sea 42 urchin the initial calcium rise is sufficient for complete oocyte activation. Recently it was shown that initial calcium release in sea urchin oocytes is caused by sperm-supplied nitric oxide synthase (NOS). In mammals, the initial calcium release is followed by a series of calcium oscillations as a prerequisite for successful oocyte activation. These oscillations are mediated by an identified soluble sperm factor. The purpose of this work was to investigate the possible role of nitric oxide synthase in mammalian oocyte activation especially in regard to calcium oscillations.
Materials and methods:
The presence of NOS in human, mouse and boar spermatozoa was investigated by SDS-PAGE and Western blot analysis and fluorescent immunocytochemistry. For microinjection experiments, mouse oocytes were isolated and loaded with the calcium-sensitive dye fluo-4-AM (20 µmol/l, 30 min) or with the nitric oxide (NO) sensitive dye DAF-DA (10 µmol/l, 60 min) and then washed. Oocytes were injected with recombinant nNOS in the presence or absence of calmodulin. In another experiment, oocytes were injected with soluble boar sperm extract in the presence or absence of an anti-NOS antibody. The course of NO production and calcium-release within the oocytes was measured with a fluorescence imaging system (Hamamatsu Photonics, Herrsching, Germany) which allows for spatial as well as temporal analysis.
Results: SDS-PAGE and Western blot analysis revealed the presence of a 90 kDa protein which reacted with anti-NOS antibody. By immunfluorescence analysis, NOS was detected as a distinct dotted stain at the midpiece region. Microinjection of recombinant nNOS caused an initial release of calcium and NO but no calcium or NO oscillations. Following co-injection of calmodulin, the initial calcium rise occurred earlier.
Injection of soluble boar sperm extract caused calcium oscillations. However, when anti-NOS antibody was co-injected with sperm extract, the initial calcium rise as well as calcium oscillations did not occur.
Conclusions: Our data show that mammalian spermatozoa contain a new form of NOS as the molecular weight of sperm NOS (90 kDa) differs from those isoforms of NOS identified hitherto (130-150 kDa)
. NOS is sufficient to cause an initial calcium rise in mammalian oocytes. However, NOS is not able to induce calcium oscillations. Therefore, mammalian oocyte activation requires NOS for initial calcium release and another factor for calcium oscillations, which is still unknown.
11.00-11.15 O-105. In-vitro maturation of oocytes: towards a daily practice?
Gaspard O., Godin P.-A., Jouan C., Dubois M., Thonon F., Hincourt N. and Foidart J.-M.
Centre de Procréation Médicalement Assistée, University of Liège, Belgium
Introduction: In an IVF cycle, about 15% of the retrieved oocytes are at a germinal vesicle stage. The competence of germinal vesicle oocytes (GVO) to maturate and undergo fertilization in classical fertilization medium is unknown. Moreover, the ability of a specific in-vitro maturation (IVM) to influence fertilization has not been documented. The aim of this study was therefore to determine if IVM in an IVM medium plus ICSI improves the maturation, fertilization, cleavage, and blastulation rates in comparison to IVM without specific maturation medium and classical IVF.
Materials and methods:
A first group of 59 germinal vesicle stage cumulus-oocyte complexes collected from 16 patients were matured in vitro in Tissue Culture Medium 199 (TCM 199, Sigma) supplemented with FSH (Puregon ® 0.075 IU/ml), HCG (Pregnyl ® 0.5 IU/ml), penicillin/ streptomycin (100 IU/ml), sodium pyruvate (0.29 mmol/l), and patient heat-inactivated serum (10%), at 37°C and under 6% O 2 , 6% CO 2 and 88% N 2 humidified atmosphere. All oocytes matured to metaphase II were injected with husband spermatozoa and then cultured in fertilization medium (FM, IVF Science) for the first 18 h, in G1-2 (IVF Science) until day 3 after fertilization, and in G2-2 (IVF Science) for blastulation. A second group of 14 GVO were kept in FM with spermatozoa for 18 h. χ 2 was used to compare both procedures, with a P value Ͻ 0.05 considered to be statistically significant.
Results:
In group I, 37 of the 59 GVO (62.7%) matured within 24 h, and an additional nine (15.3%) within 48 h. The overall maturation rate was 78.0%. Six GVO were arrested at metaphase I stage (10.2%), six at GVO stage (10.2%), and one was lysed after 24 h. Overall fertilization and cleavage rates were respectively 78.3 and 96.8% after ICSI of the matured oocytes. Fertilization rate for oocytes matured within 24 or 48 h were respectively 89.2 and 33.3%. These rates are significantly different (P Ͻ 0.02). After 2 days of culture in G1-2, a mean of 40.9% eight-cell or more embryos were obtained. The blastulation rate was 16.1% after 3 days culture in G2-2. In Group II, two GVO (14.3%) matured to the metaphase II and five to the metaphase I. Five oocytes were arrested at the GV, and two were lysed. The maturation rate in group II was significantly lower than the maturation rate in group I (P Ͻ 0.001). None of the 14 oocytes was fertilized after the incubation in FM plus spermatozoa.
Conclusions:
It is important to start IVM of the GVO at the day of retrieval. No oocytes were fertilized when kept in FM for 18 h with spermatozoa, and only two of 14 matured to metaphase II (maturation rate of 14.3%). This rate is very low when compared to maturation rate in specific IVM medium (78.0%). Furthermore, oocytes that resumed meiosis within 24 h seemed to have a greater competence to fertilization than those matured within 48 h. We will subsequently attempt to improve the low blastulation rate in group I by upgrading the culture conditions (addition of growths factors and other cytokines in IVM medium, maturation under 21% O 2 atmosphere). A further direction for this study will be the replacement of patients serum by defined solution of hormones and cytokines. We believe that this procedure will allow in-vitro maturation application in current IVF. Introduction: Though successful rates of in-vitro maturation (IVM) of immature oocytes have been established in a number of mammalian species, the subsequent viability of the embryos is invariably poor. There have been conflicting reports whether the developmental competence may be enhanced by in-vivo administration with FSH or human chorionic gonadotrophin (HCG) prior to IVM of the oocytes. The aim of this study was to determine whether in-vivo priming with FSH or HCG offers benefits to the oocytes prior to IVM that may contribute to improved development to the blastocyst stage in a mouse model.
Materials and methods:
There were four groups of female mice (C57ϫCBA) aged 3 weeks: (i) in-vivo control. Mature oocytes (metaphase II, MII) were collected from superovulated mice; (ii) IVM control. MII oocytes were collected after 24 h culture in MEM-a medium supplemented with 10% fetal calf serum (FCS), 0.1 IU/ml FSH (Gonal F; Serono), 0.5 IU/ml HCG (Pregnyl; Organon) and 0.05 mg/ml penicillin; (iii) FSH priming. Mice were injected with 7.5 IU pregnant mare's serum gonadotrophin (PMSG) 48 h prior to IVM [performed as in (ii) above]; (iv) HCG priming. Mice were injected with 5 IU HCG (Pregnyl) 16 h prior to IVM [performed as in (ii) above]. IVF was performed on the MII oocytes of all the above groups. The numbers of two-cell and blastocyst embryos were noted for each group after 24 h and 5 days respectively. The data were analysed by χ 2 .
Results: The number of MII oocytes collected, along with the fertilization and blastocyst development rates for all groups, can be seen in Table I . There were no significant differences in fertilization rates among the four groups. The rate of blastocyst formation was significantly higher in the in-vivo control group than the IVM control (P Ͻ 0.001), the FSH priming (P Ͻ 0.002) and the HCG priming (P Ͻ 0.001) groups. There were no significant differences in blastocyst rates among all three IVM groups (i.e. IVM controls, FSH priming and HCG priming). Introduction: Immobilization and injection of spermatozoa during intracytoplasmic sperm injection (ICSI) procedure requires the exposure of sperm cells to a droplet of a viscous solution in order to hinder motility. Polyvinylpyrrolidone (PVP), an artificial polymer successfully used for this purpose, has been regarded as chemically inert, although adverse effects of PVP have been reported as a result of its use of both in vivo and in vitro. Thus, we investigated the use of hyaluronate (HA), the natural component of the oocyte-cumulus complex (OCC) extracellular matrix and to which the spermatozoon is introduced on its journey towards the oocyte, as a replacement for PVP during the ICSI procedure.
Materials and Methods:
The study included two groups of patients who underwent ICSI procedure in our unit. In 104 ICSI cycles, oocytes were injected with spermatozoa that were immobilized in 10% PVP solution (control group: PVP). In 99 ICSI cycles (study group: HA) oocytes were injected with spermatozoa which were immobilized in a viscous solution of HA. Fertilization (FR), pregnancy (PR), implantation rates (IR) and sex ratio of the newborn were calculated in both groups.
Results: Mean age of the patients in the PVP group was similar to mean age of HA group (30.9 Ϯ 4.4 versus 30.7 Ϯ 4.7 years); 1154 oocytes were injected in the PVP group versus 1121 in the HA group. In comparison between PVP and HA groups no differences were observed in: FR (71.3% Ϯ 4.0 versus 72.4% Ϯ 3.8 respectively); PR (35 versus 37 pregnancies; 33.7% versus 37.4%), IR [48/359 (13.4%) 
